12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pixuvri pixantrone regulatory update

The European Commission granted conditional approval to an MAA from Cell Therapeutics for Pixuvri pixantrone to treat patients with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma. The company plans to initially make the product available through a named patient program in the EU,...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >